ErinM.(Ort)BertinoMD(She/Her)

Oncology • Columbus, OH

Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Bertino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bertino's full profile

Already have an account?

Office
810 Jasonway Ave
Ste A
Columbus, OH 43214
Phone+1 614-442-3130

Fax+1 614-442-3145

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Ohio State University HospitalResidency, Internal Medicine, 2004 - 2007
Northeast Ohio Medical UniversityClass of 2004

Certifications & Licensure

OH State Medical License 2004 - 2026
NC State Medical License 2021 - 2022
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Start of enrollment: 2011 Feb 10
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01
Completed
Phase 1
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
Active, not recruiting
Phase 2
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2020 Jun 17
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

57 citations
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygen...
Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom
Journal of Clinical Oncology. 2017-05-10
417 citations
Consensus guidelines for the management and treatment of neuroendocrine tumors.
Pamela L. Kunz, Diane Reidy-Lagunes, Lowell Anthony, Erin M. Bertino, Kari Brendtro
Pancreas. 2013-05-01
83 citations
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Random...
Thomas E. Stinchcombe, Pasi A. Jänne, Xiaofei Wang, Erin M. Bertino, Jared Weiss
JAMA Oncology. 2019-10-01

Journal Articles

Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database
Kai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central